Technical Analysis for 0UNL - Nektar Therapeutics
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 1.34 | 1.48% | 0.02 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 1.48% | |
| Wide Bands | Range Expansion | 1.48% | |
| Gapped Down | Weakness | 1.48% | |
| NR7 | Range Contraction | -4.92% | |
| Narrow Range Bar | Range Contraction | -4.92% | |
| Inside Day | Range Contraction | -4.92% |
| Alert | Time |
|---|---|
| Up 2% | 2 days ago |
| Up 1% | 2 days ago |
| 20 DMA Resistance | 2 days ago |
| Possible Inside Day | 2 days ago |
| Possible NR7 | 2 days ago |
Get a Trading Assistant
Nektar Therapeutics Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Classification
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.75 |
| 52 Week Low | 0.435 |
| Average Volume | 21,289 |
| 200-Day Moving Average | 0.69 |
| 50-Day Moving Average | 1.03 |
| 20-Day Moving Average | 1.34 |
| 10-Day Moving Average | 1.38 |
| Average True Range | 0.12 |
| RSI (14) | 55.36 |
| ADX | 36.0 |
| +DI | 28.96 |
| -DI | 20.51 |
| Chandelier Exit (Long, 3 ATRs) | 1.40 |
| Chandelier Exit (Short, 3 ATRs) | 1.20 |
| Upper Bollinger Bands | 1.73 |
| Lower Bollinger Band | 0.95 |
| Percent B (%b) | 0.5 |
| BandWidth | 57.94 |
| MACD Line | 0.10 |
| MACD Signal Line | 0.13 |
| MACD Histogram | -0.0282 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.40 | ||||
| Resistance 3 (R3) | 1.40 | 1.38 | 1.39 | ||
| Resistance 2 (R2) | 1.38 | 1.36 | 1.38 | 1.38 | |
| Resistance 1 (R1) | 1.36 | 1.35 | 1.37 | 1.36 | 1.38 |
| Pivot Point | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
| Support 1 (S1) | 1.32 | 1.32 | 1.33 | 1.32 | 1.30 |
| Support 2 (S2) | 1.30 | 1.32 | 1.30 | 1.30 | |
| Support 3 (S3) | 1.28 | 1.30 | 1.29 | ||
| Support 4 (S4) | 1.28 |
